Related Experiment Video
Updated: Apr 19, 2026

Syngeneic Mouse Orthotopic Allografts to Model Pancreatic Cancer
Published on: October 4, 2022
Epigenetic Silencing of GNMT Gene in Pancreatic Adenocarcinoma
Anca Botezatu1, Coralia Bleotu2, Anca Nastase3
1Viral Genetic Engineering Laboratory, Romanian Academy "Stefan S. Nicolau"Virology Institute, Bucharest, Romania.
Background/Aim:
Although pancreatic ductal adenocarcinoma (PDAC) remains a major challenge for therapy, biomarkers for early detection are lacking. Epigenetic silencing of tumor suppressor genes is a majorcontributor to neoplastic transformation. The aim of this study was to identify new factors involved in PDAC progression. The GNMT gene possesses CpG islands in the promoter region and is important in methyl-group metabolism and in maintaining a normal methylation status of the genome.
Materials And Methods:
To test the hypothesis whether GNMT is epigenetically regulated in PDAC, we evaluated the GNMT gene expression and promoter methylation status in 30 paired samples of PDAC and normal pancreatic tissue.
Results:
We found significantly higher methylation frequencies (p<0.001) in PDACs (2.82-100%; median, 36.05%) than in controls (0.28-14.02%; median, 4.39%). The GNMT gene expression was decreased in PDACs compared to normal pancreatic tissues in 26/30 cases (86.67%). Furthermore, we showed that treatment with 5-aza-2-deoxycytidine (5-aza-dC) increased GNMT mRNA expression and decreased viability in PDAC cells.
Conclusion:
Collectively, these data indicate that GNMT is aberrantly methylated in PDAC representing, thus, a potential major mechanism for gene silencing. Methylation of GNMT gene is directly correlated with disease stage and with tumor grade indicating that these epigenetic effects may be important regulators of PDAC progression.
Insights
Aberrant methylation of the GNMT gene is a key mechanism in pancreatic ductal adenocarcinoma (PDAC) progression. This epigenetic silencing correlates with disease stage and tumor grade, offering potential biomarkers for early detection.
Area of Science:
- Epigenetics
- Cancer Biology
- Molecular Oncology
Background:
- Pancreatic ductal adenocarcinoma (PDAC) lacks early detection biomarkers.
- Epigenetic silencing of tumor suppressor genes contributes to cancer development.
- The GNMT gene plays a role in maintaining genome methylation status.
Purpose of the Study:
- To investigate the epigenetic regulation of the GNMT gene in PDAC.
- To identify novel factors involved in PDAC progression.
Main Methods:
- Evaluated GNMT gene expression and promoter methylation in 30 paired PDAC and normal pancreatic tissues.
- Assessed the effect of 5-aza-2-deoxycytidine (5-aza-dC) on GNMT expression and PDAC cell viability.
Main Results:
- Significantly higher GNMT promoter methylation frequencies were observed in PDAC compared to normal tissues (median 36.05% vs. 4.39%).
- GNMT gene expression was decreased in 86.67% of PDAC cases.
- 5-aza-dC treatment increased GNMT mRNA expression and reduced PDAC cell viability.
Conclusions:
- Aberrant methylation of the GNMT gene is a major mechanism for gene silencing in PDAC.
- GNMT methylation is directly correlated with PDAC disease stage and tumor grade.
- Epigenetic regulation of GNMT may be crucial in PDAC progression.
More Related Videos
06:07Continuous Fluorescence-Based Endonuclease-Coupled DNA Methylation Assay to Screen for DNA Methyltransferase Inhibitors
Published on: August 5, 2022
07:44Surgical Injury to the Mouse Pancreas through Ligation of the Pancreatic Duct as a Model for Endocrine and Exocrine Reprogramming and Proliferation
Published on: August 7, 2015
Related Concept Videos
Genomic Imprinting and Inheritance
The expression of some genes depends on which parent passed the gene to the offspring, through a phenomenon known as...
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Abnormal Proliferation
MicroRNAs
MicroRNAs